Statin intake is associated with MMP‐1 level in gingival crevicular fluid of patients with periodontitis. (26th April 2016)

• Record Type: Journal Article
• Authors: Poston, CJ; Pierce, TC; Li, Y; Brinson, CW; Lu, Z; Lauer, AW; Leite, RS; Huang, Y
• Is Part Of: Oral diseases. Volume 22:Number 5(2016)
• Page Start: 438
• Page End: 444
• Publication Date: 2016-04-26
• Subjects: statin -- periodontitis -- diabetes mellitus -- matrix metalloproteinase‐1; Mouth -- Diseases -- Research -- Periodicals; 617.522
• DOI: 10.1111/odi.12474
• Languages: English
• ISSNs: 1354-523X

Abstract

Abstract : Background: This study was conducted to assess whether statin intake is associated with clinical parameters of periodontitis and matrix metalloproteinase (MMP) levels in gingival crevicular fluid (GCF) of non‐diabetic and diabetic patients. Methods: We first determined the effect of simvastatin on MMP expression in mononuclear cells. We then recruited 117 non‐diabetic and diabetic patients, who all had periodontitis and took or did not take statin, and measured periodontal probing depth (PPD) and clinical attachment level (CAL), and collected gingival crevicular fluid (GCF) to quantify MMPs. Results: The in vitro studies showed that simvastatin potently inhibited the expression of MMP‐1, MMP‐8, and MMP‐9 upregulated by lipopolysaccharide (LPS) and high glucose in mononuclear cells. The patient study showed that, after adjusting for age and smoking status, PPD in diabetic patients on statin was significantly less than that in diabetic patients not on statin. MMP‐1 level in GCF of non‐diabetic and diabetic patients on statin was lower than that of non‐diabetic and diabetic patients not on statin, respectively. No difference was found for MMP‐8 and ‐9 levels in GCF. Conclusion: Statin intake is associated with reduced PPD in diabetic patients and MMP‐1 level in GCF in either non‐diabetic or diabetic patients.